Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of TP-03 (Xdemvy) in Healthy Adults
NCT05138861Phase 1Completed
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lotilaner in Demodex blepharitis (DB), sponsored by Tarsus Pharmaceuticals, Inc. Primary endpoints: Plasma concentration of lotilaner at 42 Days, Treatment Emergent Adverse Events at 42 Days and 8 more. Started Feb 2021; status: completed.
02
Drugs
lotilaner
03
Conditions
Demodex blepharitis (DB)
Beyond the preview
Go deeper on NCT05138861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05138861.